CN110662535A - 用于治疗与线粒体活性氧(ros)产生相关的疾病的去甲基茴三硫衍生物 - Google Patents

用于治疗与线粒体活性氧(ros)产生相关的疾病的去甲基茴三硫衍生物 Download PDF

Info

Publication number
CN110662535A
CN110662535A CN201880029927.4A CN201880029927A CN110662535A CN 110662535 A CN110662535 A CN 110662535A CN 201880029927 A CN201880029927 A CN 201880029927A CN 110662535 A CN110662535 A CN 110662535A
Authority
CN
China
Prior art keywords
ros
day
compound
production
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880029927.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·迪奥莱兹
F·马林
O·佩提特金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Op2 Drug Co
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
National Institute of Health Sciences
Original Assignee
Op2 Drug Co
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
National Institute of Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Op2 Drug Co, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux, National Institute of Health Sciences filed Critical Op2 Drug Co
Priority claimed from PCT/EP2018/055651 external-priority patent/WO2018162581A1/en
Publication of CN110662535A publication Critical patent/CN110662535A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CN201880029927.4A 2017-03-07 2018-03-07 用于治疗与线粒体活性氧(ros)产生相关的疾病的去甲基茴三硫衍生物 Pending CN110662535A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762467874P 2017-03-07 2017-03-07
US62/467874 2017-03-07
EP17159691 2017-03-07
EP17159691.9 2017-03-07
PCT/EP2018/055651 WO2018162581A1 (en) 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Publications (1)

Publication Number Publication Date
CN110662535A true CN110662535A (zh) 2020-01-07

Family

ID=61628329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029927.4A Pending CN110662535A (zh) 2017-03-07 2018-03-07 用于治疗与线粒体活性氧(ros)产生相关的疾病的去甲基茴三硫衍生物

Country Status (10)

Country Link
US (1) US11484529B2 (enExample)
EP (1) EP3592348A1 (enExample)
JP (1) JP2020511450A (enExample)
KR (1) KR20190129900A (enExample)
CN (1) CN110662535A (enExample)
AU (1) AU2018232799B2 (enExample)
BR (1) BR112019018495A2 (enExample)
CA (1) CA3055122A1 (enExample)
IL (1) IL269127A (enExample)
RU (1) RU2019131478A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112546216A (zh) * 2020-11-20 2021-03-26 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049166A1 (en) * 2018-09-06 2020-03-12 OP2 Drugs Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
EP4259124A1 (en) * 2020-12-10 2023-10-18 Marin, Frédéric Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
JP2024506053A (ja) * 2021-02-09 2024-02-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 複合体ｉの制御剤
CN114414332B (zh) * 2022-01-05 2024-04-16 北京科技大学 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法
CN119185368A (zh) * 2024-09-26 2024-12-27 中南大学 具有线粒体序贯靶向能力的强抗氧化性纳米药物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
CN102807557A (zh) * 2012-08-21 2012-12-05 苏州大学 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
KR20030067935A (ko) 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
WO2001091118A1 (fr) * 2000-05-22 2001-11-29 Clarion Co., Ltd. Lecteur de disque
CN1355156A (zh) * 2000-11-27 2002-06-26 朱国和 含有造纸废料污泥的微生物菌肥及其制备方法
CN1244325C (zh) 2001-05-11 2006-03-08 成都国嘉联合制药有限公司 胆维他在制药中的应用
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
EP1474131B1 (en) 2002-02-13 2006-11-22 Solvay Pharma Use of anethole dithiolethione in lung cancer chemoprevention
TW200640898A (en) 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
WO2008106640A1 (en) 2007-03-01 2008-09-04 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
CN102961376B (zh) * 2012-11-06 2015-06-10 暨南大学 HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用
CN102961375B (zh) 2012-12-05 2015-01-14 苏州大学 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
CN102807557A (zh) * 2012-08-21 2012-12-05 苏州大学 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112546216A (zh) * 2020-11-20 2021-03-26 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用

Also Published As

Publication number Publication date
US20210154175A1 (en) 2021-05-27
IL269127A (en) 2019-11-28
JP2020511450A (ja) 2020-04-16
BR112019018495A2 (pt) 2020-04-14
CA3055122A1 (en) 2018-09-13
AU2018232799B2 (en) 2021-11-25
AU2018232799A1 (en) 2019-10-03
KR20190129900A (ko) 2019-11-20
EP3592348A1 (en) 2020-01-15
US11484529B2 (en) 2022-11-01
RU2019131478A3 (enExample) 2021-07-09
RU2019131478A (ru) 2021-04-07

Similar Documents

Publication Publication Date Title
US11318113B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
CN110662535A (zh) 用于治疗与线粒体活性氧(ros)产生相关的疾病的去甲基茴三硫衍生物
JP7054691B2 (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
Deng et al. Multifunctional supramolecular filament hydrogel boosts anti‐inflammatory efficacy in vitro and in vivo
KR20180073554A (ko) 중수소화 화합물 및 이의 용도
JP2008110962A (ja) Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
Yusuf et al. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease
WO2018162581A1 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
CN113347972B (zh) 治疗线粒体功能障碍的方法和制剂
Trzeciecka et al. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa
Geva et al. Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
BR112021003997A2 (pt) composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma
KR20120110117A (ko) 네포팜 화합물을 사용하는 흉터 및 베타-카테닌-매개된 질환의 치료방법
CA3005527C (fr) Mirabegron pour le traitement de maladies retiniennes
US10653668B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
RU2775597C2 (ru) Ингибитор продукции реактивных форм кислорода для лечения заболеваний, связанных со свободными радикалами кислорода
Hu et al. Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma
US20250179024A1 (en) Amyloid and associated pathology modulators and methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200107

WD01 Invention patent application deemed withdrawn after publication